Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Real-World Data, AI Play Key Roles In COVID-19 Vaccine Programs

Executive Summary

RWD has helped with development of multiple SARS-CoV-2 vaccines already and could be a useful tool for the future, as panelists discussed at the AI Cures conference.

You may also be interested in...



Coronavirus Update: AstraZeneca’s Vaccine Trials Cleared To Restart In the US, J&J Prepares To Restart Its Vaccine Study

Two potential COVID-19 vaccine trials from AstraZeneca and Johnson & Johnson are set to resume in the US following temporary pauses due to safety concerns. Data from both could come later this year.

J&J Says It's Wait And See On COVID-19 Vaccine Delay, Outlines Rosier Outlook for 2021

It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.

ATAI Raises $125m Series C To Expand The Boundaries In Mental Health

The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel